Jason Broderick

Sprycel Approved for CML Subset

November 10, 2017

Sprycel (dasatinib), an oral medication that helps reduce the production of damaged white blood cells, has been approved by the Food and Drug Administration for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Ibrance Delays Progression of Breast Cancer in Phase 3 Trial

April 16, 2015

The PALOMA-3 trial examining an Ibrance (palbociclib) regimen in HR-positive/HER2-negative breast cancer was halted after an independent panel determined it met the primary endpoint of improving progression-free survival.

Chemo Alone May Be Optimal for Some HER2-Positive Breast Cancer Patients

December 11, 2014

Research presented at the 2014 San Antonio Breast Cancer Symposium shows that high levels of lymphocytes, white blood cells found in the immune system, could help identify women with HER2-positive breast cancer who could forego chemotherapy.